Deepwise Medical Completes New RMB 500 Million Funding Round to Advance End-to-End, Full-Scenario AI-Powered Digital Healthcare Solutions

Recently,DeepWise Announces Completion of New Funding RoundDeepWise has announced the completion of its latest funding round, co-led by Legend Capital and the Hangzhou Municipal Industrial Fund. The total financing amount reached nearly RMB 500 million, fully demonstrating the capital market’s strong recognition of and confidence in DeepWise. This funding will accelerate DeepWise’s exploration and innovation, enabling the company to continue developing industry-leading AI products and solutions and further empower the healthcare ecosystem.

DeepWise is a national high-tech enterprise that actively responds to national policies by building a multimodal product architecture centered on technological, scientific, and business model innovation. It provides thousands of medical institutions with comprehensive, full-scenario AI-driven digital intelligence services, covering personal health smart management, AI-assisted diagnosis, clinical decision support, intelligent disease screening, patient services, and research training. Since its establishment, the company has experienced robust growth. Currently ranking among the industry leaders with 14 Class III medical device certificates issued by the National Medical Products Administration (NMPA), DeepWise’s AI products are used nearly 200 million times annually, establishing it as a representative force of new quality productive forces.

Recently, the National Health Commission, the National Administration of Traditional Chinese Medicine, and the National Disease Control and Prevention Administration jointly issued the "Reference Guidelines for Artificial Intelligence Application Scenarios in the Health Sector." This document outlines 84 specific AI application scenarios across four key areas, charting the development direction for medical AI enterprises. In recent years, medical AI companies have sprung up like mushrooms after rain; however, many have struggled to survive due to various challenges, with only a few possessing both technological and market barriers managing to stand out. Throughout its journey, DeepWise has consistently upheld a spirit of resilience and perseverance. Amidst fierce competition in the medical AI sector, it has never retreated, instead leveraging this tenacity to continuously explore paths of innovation. Since its establishment, DeepWise has achieved significant breakthroughs in AI product R&D, expansion of AI application scenarios, translation of scientific research outcomes, and technological innovation. It has continuously broadened the application of artificial intelligence technologies in areas such as assisted diagnosis, clinical big data governance, data asset conversion, clinical decision support, personal health management, and smart equipment. By collaborating with governments at all levels and medical institutions, DeepWise has implemented practical applications in more than 30 provinces and municipalities across China. These efforts have helped physicians improve the efficiency and precision of diagnosis and treatment, provided high-quality medical services to patients, and offered optimal solutions for quality improvement and efficiency enhancement to healthcare institutions. With widespread and comprehensive deployment of its products, DeepWise has delivered impressive market performance, maintaining a leading position in the industry. This "DeepWise Model," which combines industry insight with sustained technological innovation capability, is nearly impossible to replicate in the market. In the current environment of a capital winter, the mid-to-late stage medical investment market has entered a period of hibernation. DeepWise’s successful financing serves as an affirmation by both the industry and investors of its outstanding performance in the medical AI field, as well as a vote of confidence in its future ability to further promote the deep integration of AI technologies across all processes and scenarios in healthcare.

Joe Xin, Co-founder and CEO of DeepWise, stated, “We extend our gratitude to all investors of DeepWise for their support and trust in our corporate development, which serves as the foundation for our persistent innovation and continuous progress in this industry. This round of financing represents strong market recognition of DeepWise’s technological capabilities and growth prospects. Seizing this opportunity, we will continue to align closely with national policies, accelerate technological innovation and product commercialization, and deepen the application of artificial intelligence technologies in various healthcare scenarios. By delivering higher-quality products and services, we aim to bring greater possibilities to the medical industry, contribute to the Healthy China initiative, and ensure that AI technology benefits a broader population.”

New shareholders in this funding round, Hangzhou Innovation Fund and Yuhang Industrial Fund, stated that their investment decision in DeepWise was based on deep insights and forward-looking analysis of the “AI + Healthcare” sector, particularly the industry transformation opportunities driven by breakthroughs in AI algorithms and computing power. As a pioneer in the application of artificial intelligence in healthcare, especially in the mature and commercially implemented scenario of AI-assisted diagnosis for medical imaging, DeepWise has demonstrated promising innovative capabilities and market leadership.

The number of hospitals where DeepWise’s products have been deployed, along with the quantity of Class III medical device certifications it holds, serves as strong evidence of its commercialization capabilities and technological prowess. DeepWise’s management team, characterized by strategic vision and exceptional execution, forms the cornerstone of the company’s continuous innovation and rapid growth.The Hangzhou Innovation Fund and Yuhang Industry Fund will fully support DeepWise’s innovation and development in the field of medical AI. We look forward to partnering with DeepWise to jointly drive innovation and progress in the healthcare industry, creating greater value for society.

Regarding this financing round, Legend Capital stated that the artificial intelligence (AI) industry is in a phase of rapid development, transitioning from laboratory research to industrialization. Healthcare represents a critical application scenario for AI, which demonstrates significant potential value in medical settings such as assisted diagnosis, clinical decision support, and treatment efficacy evaluation. The deep integration of AI with healthcare can enhance efficiency across the entire medical care continuum, holding promise for alleviating the current shortage of per capita medical resources in China.

DeepWise is a pioneer in China’s medical AI sector, holding a leading position in scientific research, product development, and commercialization. Evolving from imaging AI to multimodal AI-powered smart solutions, DeepWise provides hospitals with richer and more accurate diagnostic data, thereby advancing clinical practice and scientific research.

Legend Capital remains bullish on the application prospects of artificial intelligence in healthcare. We are honored to co-invest in DeepWise’s latest financing round alongside the Hangzhou Innovation Fund and Yuhang Industrial Fund. Working hand in hand with the company and its team, we are committed to advancing AI-driven medical technologies to benefit more patients.

Looking ahead, DeepWise will continue to align closely with policy developments, constantly expand the application boundaries of medical AI, assist physicians in improving diagnostic and therapeutic efficiency and accuracy, empower primary healthcare, and promote the decentralization of high-quality medical resources through innovative technologies. We remain committed to exploring next-generation artificial intelligence technologies, such as large language models and AIGC, to build a multimodal, one-stop AI platform that better supports the intelligent transformation of clinical practice. By deepening collaborations with more medical institutions and research universities, we will accelerate the implementation and translation of cutting-edge technologies, drive the intelligent transformation of the entire healthcare industry, continue to lead the medical AI sector, and write many more chapters of excellence.